Story perspectives

Datroway Outperforms Chemo in Triple-Negative Breast Cancer

10/20/2025

Summary

Datroway Achieves Survival Milestone

AstraZeneca and Daiichi Sankyo announced at the European Society for Medical Oncology Congress that Datroway achieved median overall survival of 23.7 months in triple-negative breast cancer, versus 18.7 months with chemotherapy.
Datroway is an antibody-drug conjugate targeting tumor cells while sparing healthy tissue.
Datroway's U.S. approval earlier this year may treat 90% of women with breast cancer.
The trials compared Datroway with Gilead's Trodelvy, underscoring its competitive edge.

Summary

Sacituzumab Boosts Survival

Sacituzumab govitecan significantly improves progression-free survival in previously untreated, unresectable triple-negative breast cancer (TNBC) patients ineligible for immune checkpoint inhibitors, according to ASCENT-03 results at the 2025 ESMO Congress.
In a 558-patient trial, median PFS was 9.7 months with sacituzumab govitecan versus 6.9 months.
The objective response rate was similar, while duration of response was 12.2 vs 7.2 months.
Safety was manageable, with neutropenia and infections as adverse events.

1 of 2

Datroway Achieves Survival Milestone

AstraZeneca and Daiichi Sankyo announced at the European Society for Medical Oncology Congress that Datroway achieved median overall survival of 23.7 months in triple-negative breast cancer, versus 18.7 months with chemotherapy.
Datroway is an antibody-drug conjugate targeting tumor cells while sparing healthy tissue.
Datroway's U.S. approval earlier this year may treat 90% of women with breast cancer.
The trials compared Datroway with Gilead's Trodelvy, underscoring its competitive edge.

1 / 2